IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG-2(-/-) mice via peroxisome proliferator-activated receptor-gamma activation. - Archive ouverte HAL Access content directly
Journal Articles Journal of Immunology Year : 2008

IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG-2(-/-) mice via peroxisome proliferator-activated receptor-gamma activation.

Agnès Coste
Céline Lagane
  • Function : Author
Cédric Filipe
  • Function : Author
Hélène Authier
  • Function : Author
Amandine Galès
  • Function : Author
Victorine Douin-Echinard
Jean-Claude Lepert
  • Function : Author
Patricia Balard
  • Function : Author
Marie-Denise Linas
  • Function : Author
Jean-François Arnal
  • Function : Author

Abstract

We recently demonstrated that in vitro peroxisome proliferator-activated receptor-gamma (PPARgamma) activation of mouse peritoneal macrophages by IL-13 or PPARgamma ligands promotes uptake and killing of Candida albicans through mannose receptor overexpression. In this study, we demonstrate that i.p. treatment of immunocompetent and immunodeficient (RAG-2(-/-)) mice with natural and synthetic PPARgamma-specific ligands or with IL-13 decreases C. albicans colonization of the gastrointestinal (GI) tract 8 days following oral infection with the yeast. We also showed that Candida GI infection triggers macrophage recruitment in cecum mucosa. These mucosal macrophages, as well as peritoneal macrophages, overexpress the mannose receptor after IL-13 and rosiglitazone treatments. The treatments promote macrophage activation against C. albicans as suggested by the increased ability of peritoneal macrophages to phagocyte C. albicans and to produce reactive oxygen intermediates after yeast challenge. These effects on C. albicans GI infection and on macrophage activation are suppressed by treatment of mice with GW9662, a selective PPARgamma antagonist, and are reduced in PPARgamma(+/-) mice. Overall, these data demonstrate that IL-13 or PPARgamma ligands attenuate C. albicans infection of the GI tract through PPARgamma activation and hence suggest that PPARgamma ligands may be of therapeutic value in esophageal and GI candidiasis in immunocompromised patients.
No file

Dates and versions

hal-00283071 , version 1 (29-05-2008)

Identifiers

  • HAL Id : hal-00283071 , version 1
  • PUBMED : 18354219

Cite

Agnès Coste, Céline Lagane, Cédric Filipe, Hélène Authier, Amandine Galès, et al.. IL-13 attenuates gastrointestinal candidiasis in normal and immunodeficient RAG-2(-/-) mice via peroxisome proliferator-activated receptor-gamma activation.. Journal of Immunology, 2008, 180 (7), pp.4939-47. ⟨hal-00283071⟩
52 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More